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Background: Exacerbations of chronic obstructive pulmonary disease (COPD) significantly
contribute to COPD-related morbidity. Diagnosis of COPD exacerbations may be improved by
analyzing biomarkers such as alpha-1 antitrypsin (AAT). AAT is an acute-phase protein and
inhibitor of neutrophil elastase. Deficiency of AAT may result in early-onset respiratory symp-
toms. Measurement of exhaled breath condensate (EBC) is a noninvasive method to investigate
biomarkers present in the epithelial lining fluid, such as AAT.
Objective: To investigate whether AAT can be detected and quantified in EBC and to compare
AAT levels in the EBC of healthy controls, patients with COPD, and during exacerbations of COPD.
Methods: EBC from 10 healthy controls, 17 subjects with COPD, and 18 subjects with exacerba-
tions of COPDwas collectedwith the RTube device. AAT fromEBC and serumwere quantified by
ELISA.
Results: AAT in EBC was detectable in every individual. Patients with exacerbations of COPD had
significantly increased AAT values (mean, 514.33 pg/mL, [SD 279.41 ]) compared with healthy
controls (mean, 251.32 pg/mL, [SD 44.71]) and stable COPD patients (mean, 242.01 pg/mL [SDsin; ANOVA, one-way analysis of variance; COPD, chronic obstructive pulmonary disease; CRP, C-
condensate; ELF, epithelial lining fluid; GOLD, Global initiative for chronic Obstructive Lung Disease;
ed saline; PCT, procalcitonin; WBC, white blood cell; CI, confidence interval; NS, no significant; HC,
-marburg.de (A.R. Koczulla).
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AAT levels in COPD Exacerbations 12165.74]) (PZ 0.0003; PZ 0.00003). EBC AAT showed only a correlation trend with serum AAT
(rZ 0.3, PZ 0.054).
Conclusions: AAT in EBC was detectable and quantifiable. AAT measured in EBC was
significantly increased during exacerbations of COPD and can potentially be used as a biomarker
in exacerbations.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
One important factor in the pathogenesis of chronic obstruc-
tive pulmonary disease (COPD) is believed to be inflammation
of the small airways caused by inhalation of particles and
gases.1 Two main mechanisms are thought to lead to inflam-
mation which causes pathological changes in lung tissue:
production of reactive oxygenmetabolites and disturbance of
the physiological protease-antiprotease balance. One of the
principal antiproteases is alpha-1 antitrypsin (AAT).
The main function of AAT is to protect the lungs against
the protease neutrophil elastase, which is produced in
response to infection and inflammation, and when not
neutralized by AAT, destroys lung tissue. Furthermore, AAT
is an acute-phase protein and an anti-inflammatory media-
tor.2e4 It has been shown that AAT is elevated in the serum
of patients with acute systemic and pulmonary infections.5,6
Recently, there has been increasing interest in using
exhaled breath condensate (EBC) as a simple, noninvasive
method to sample the lower respiratory tract for markers of
inflammation.15,16,20 The measurement of EBC is an easy
and inexpensive method, however, there are still problems
regarding standardization of the procedure.7
The diagnosis and classification of COPD exacerbations
may be improved by the analysis of biomarkers. During
acute COPD exacerbations, changes in the levels of chem-
ical and inflammatory markers have been found. A number
of potential markers have been investigated for use as
markers for exacerbation of COPD, such as H2O2 in exhaled
air or interleukin (IL)-8 and the soluble cell adhesion
molecule sICAM in serum.8,9 None of these markers have yet
been used in routine clinical practice.
Initial investigations indicate that AAT can be detected
in EBC, which may reflect AAT levels in the epithelial lining
fluid (ELF).10 AAT has not yet been sufficiently quantified in
the EBC of patients with acute exacerbations of COPD.
However, AAT may have potential as a marker in exacer-
bations because of its role in the disease as a chemo-
attractant for neutrophils and as an anti-inflammatory and
antimicrobial protein. The aims of this study were to detect
and compare AAT in the EBC of healthy controls, in patients
with COPD, and in patients with acute exacerbations of
COPD, and, to determine whether levels of AAT in serum
and EBC are correlated.
Methods
Design
This observational cohort study aimed to test whether AAT
is detectable in the EBC of patients with acuteexacerbations of COPD. As controls, healthy subjects and
COPD patients during stable disease were enrolled.Subjects
EBC was collected from 10 healthy nonsmoking controls,
17 stable COPD patients, and 18 acute exacerbated COPD
patients of comparable age. COPD patients were
categorized according to Global initiative for chronic
Obstructive Lung Disease (GOLD) criteria11,12 and graded
as Stages IeIV.13 Acute exacerbated COPD patients were
chosen according to criteria described by Cazzola et al.14
No subjects approached to take part in the study
declined.
All patients underwent a single study visit where EBC
was collected once. Acutely exacerbated COPD patients,
who had not received systemic steroids, were recruited and
their EBC collected in the hospital emergency area during
the first 60 min within presentation to the hospital.
Unstable patients who needed respiratory ventilation
support, or who were referred to intensive care, were not
included. Every patient received a chest X-ray. Patients
with pneumonia were excluded. All participants gave
informed consent and the study (No. 0.59/06) was approved
by the Philipps University Marburg local ethics committee.
The study was planned as an observational cohort study
with a limited number of subjects and was not registered as
a clinical trial.EBC collection
EBC samples were collected during 10 min of quiet
breathing through a single-use disposable RTube collector
(Respiratory Research, Inc.; Charlottesville, VA), while
subjects were wearing a nose clip. The aluminum sleeve of
the device had been cooled to an initial temperature of
20 C prior to collection.15,16ELISA assay of AAT in EBC
A total of 1 mL of EBC was lyophilized using a speed vac
(Bachofer; Reutlingen, Germany) and resuspended as
100 ml/well using 0.1% Tween in phosphate-buffered
saline (PBS). ELISA was performed using anti-human AAT
rabbit antibody (SigmaeAldrich; Taufkirchen, Germany)
(1:200 dilution), followed by horseradish-marked goat
anti-AAT (Bethyl Laboratories, Inc.; Montgomery, TX)
(1:2000 dilution). Absorption was detected with a Tecan
Ultra 384 Reader (Tecan; Crailsheim, Germany) at
450 nm.
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Western blots were performed using anti-human AAT anti-
body (SigmaeAldrich; Taufkirchen, Germany) (1:5000 dilu-
tion), followed by anti-rabbit (Pierce; Bonn, Germany)
(1:1000 dilution). The membrane was incubated using
a chemiluminescence kit (Super Signal West Femto
Maximum Sensitivity Substrate, Pierce, Rockford).
Serum analysis and white blood cell (WBC) count
Serum AAT measurements were performed using a routine
ELISA kit for all samples. Serum C-reactive protein (CRP)
levels, WBC count, and procalcitonin (PCT) were measured
for every subject.
Data analysis
Statistical analysis was performed using Sigma stat and
Graphpad 5.0 software. Data are presented as mean SD.
The Wilcoxon matched-pairs signed-ranks test was
employed. Differences between values of groups were
explored by one-way analysis of variance (ANOVA). Correla-
tion analysis was performed using Spearman’s correlation
coefficient.
Results
Subjects
Patient characteristics are reported in Table 1. Healthy
subjects were 36.1 11.5 years old, patients with stable
COPD were 66.6 7.8 years old, and patients with acute
exacerbated COPD were 72.2 11.8 years old (Table 1).
Levels of AAT in EBC of exacerbated COPD patients
measured by ELISA assay
It was possible to obtain EBC in stable COPD and also in
exacerbated COPD patients. AAT mean values were
251.32 pg/mL (SD 44.71) for healthy controls, 242.01 pg/mL
(SD 65.74) for stable COPD, and 514.33 pg/mL (SD 279.41)
for exacerbated COPD subjects (Fig. 1a). Exacerbated COPD
patients had significantly elevated AAT levels compared
with healthy controls (PZ 0.0003) and stable COPDTable 1 Patient characteristics. No significant differences for l
COPD and exacerbated COPD patients (Wilcoxon rank sum test).
Gender COPD (GOLD grade) FEV1/VC
% pred.
Age
(yearsI II III IV
Control 6 M/4 F e e e e 103.5 36.1
SD e e e e e 6.8 11.5
COPD 11 M/6 F 2 8 7 e 56.3 66.6
SD e e e e e 17.5 7.8
COPD ex 13 M/5 F 1 4 6 7 59.2 72.2
SD e e e e e 14.5 11.8
P-value
(Wilcoxon)
e e e e e 0.632 0.07patients (PZ 0.00003). One clinically stable patient was
excluded from statistical analysis because of serum signs of
systemic inflammation with clearly elevated CRP, PCT, and
WBC values and radiological signs of pneumonia.
Western blot detection of AAT in EBC
AAT spiking experiments showed that the assay detected
the added AAT. In Western blot experiments, AAT was
visible at 54 kD (data not shown).
Levels of AAT in the serum of exacerbated COPD
patients
Serum levels of AAT were analyzed to determine whether
these levels were increased during acute COPD exacerba-
tions. Serum levels of AAT, for healthy controls were 1.29 g/
L (SD 0.13), for COPD subjects 1.49 g/L (SD 0.22), and for
subjects with acute exacerbations of COPD 1.85 g/L (SD
0.53). Patients with acute exacerbated COPD had signifi-
cantly elevated AAT serum levels (PZ 0.00015) compared
with healthy controls and stable COPD patients (Fig. 1b).
Correlation between serum AAT and EBC AAT
To answer the question whether AAT levels in serum and
EBC were correlated, we calculated the Spearman’s
correlation coefficient for the EBC and the serum AAT levels
of the study subjects (rZ 0.3), which did not reach
statistical significance (PZ 0.054) (Fig. 2).
Levels of CRP, PCT, and WBC in patients with
acute exacerbated COPD
To find evidence for a systemic component of the COPD
exacerbation, serum CRP, WBC count, and serum PCT were
measured (Fig. 3). Mean CRP was <5 mg/L (SD 0) in healthy
controls, 6.59 mg/L (SD 3.55) in stable COPD patients, and
31.72 mg/L (SD 44.9) in exacerbated COPD patients
(Fig. 3a). The differences reached statistical significance
(healthy controls vs stable COPD; PZ 0.035, healthy
controls vs acute exacerbated COPD; PZ 0.0006, stable
COPD vs acute exacerbated COPD; PZ 0.003).
Mean PCT was 0.12 (SD 0.04) in healthy controls, 0.1 (SD
0) in stable COPD patients, and 0.21 (SD 0.27) in patientsung function, age and smoking were found, comparing stable
)
Smoking
history (py)
Current/
ex-smoker
Inhaled
steroids
b-Mimetics Tiotropium
4 0/3 e e e
7,4 e e e e
38.8 3/14 13/17 13/17 12/17
21.5 e e e e
43.9 1/17 11/18 11/18 16/18
26.4 e e e e
0.987 e e e e
a0
500
1000
1500
AAT ELISA from EBC
p=0.0003___________________________
p=0.00003___________
p=NS___________
p
g
 A
A
T
/
m
l
Serum AAT ELISA
0
1
2
3
4
p=0.00015______________________________
p=0.04_______________
p=0.0036____________
A
A
T
 
g
/
L
b
Fig. 1 (a). Comparison of EBC AAT values (with standard
errors of mean) obtained by RTube in healthy controls, in
patients with COPD, and in patients with an acute exacerbation
of COPD AAT values in patients with an acute exacerbation of
COPD were significantly higher than in healthy controls
(PZ 0.0003) and stable COPD (PZ 0.00003) patients. (b)
Comparison of serum AAT values in healthy controls, patients
with COPD, and patients with an acute exacerbation of COPD
AAT values (with standard errors of mean) in patients with an
acute exacerbation of COPD were significantly higher than in
healthy controls (PZ 0.00015) and stable COPD patients
(PZ 0.04).
Correlation EBC-Serum AAT
0 1 2 3 4
0
500
1000
1500
Spearman R=0.3
CI: [-0,01371 - 0,5599]
p=0.054
Serum AAT g/L
E
B
C
 
i
n
 
p
g
/
m
l
Fig. 2 Serum and EBC AAT values show a correlation trend
(PZ 0.05). The Spearman’s correlation coefficient is rZ 0.3.
AAT levels in COPD Exacerbations 123with acute exacerbations of COPD (Fig. 3b). No significance
was found when comparing the PCT values in the healthy
controls, COPD stable, and acute exacerbated COPD
groups. Mean WBC count was 6.62 g/L (SD 2.02) in healthy
controls, 7.44 g/L (SD 1.63) in stable COPD patients, and
11.83 g/L (SD 3.95) in exacerbated COPD patients (Fig. 3c).
In terms of the WBC count, we found significant differences
by comparing healthy controls with exacerbated COPD
patients (PZ 0.0006), stable COPD patients withexacerbated COPD patients (PZ 0.0007) and stable COPD
patients with healthy controls (PZ 0.03).
The levels of AAT in the serum of patients with acute
exacerbated COPD were significantly correlated with CRP in
serum; Spearman’s r was 0.87 (PZ 0.000003) (Fig. 3d).
Acute exacerbated COPD serum AAT was also observed to
correlate with PCT (Spearman’s rZ 0.56, PZ 0.017; data
not shown). No significant correlation was found between
serum AAT and WBC (Spearman’s rZ 0.24, PZ 0.13).
Moreover for all included subjects there was no corre-
lation found between EBC AAT and serum CRP (Spearman’s
rZ 0.24, PZ 0.13), PCT (Spearman’s rZ0.135, PZ 0.4)
but for WBC (Spearman’s rZ 0.48, PZ 0.0013) data not
shown.
Discussion
The main findings of this paper are that AAT is significantly
elevated in the EBC and serum of exacerbated COPD
patients, and that AAT levels in serum and EBC have a trend
to be positively correlated. Significant differences were
observed when WBC counts and CRP in healthy controls and
stable COPD patients were compared with the count in
exacerbated COPD patients. Regarding PCT, the differences
were not statistically significant but correlations were
found between serum AAT with PCT and AAT with CRP in
serum.
A previous EBC study showed that AAT is detectable in
EBC, but AAT concentrations reached the lower limit of
detection or quantification (0.8 ng/mL) in only 19.6% of
subjects.10 In our assay the limit of detection was less, and
the difference between the two studies may have been that
we used different antibodies. AAT spiking experiments
showed that the assay indeed detected the added AAT. In
Western blot experiments a positive band was visualized at
54 kD, the size of AAT. We were able to improve the ELISA
reaching down to a sensitivity range below 0.1 ng/mL. At
a threshold of 0.3 ng/ml there is a sensitivity of 0.89 and
a specificity of 0.78. Find further description of the ELISA in
the provided supplement.
The observation that EBC AAT was significantly elevated
in exacerbated COPD patients is likely to be explained by
the acute-phase response of AAT. In EBC, exacerbated
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Fig. 3 (a) Comparison of serum CRP in healthy controls, patients with COPD, and patients with an acute exacerbation of COPD.
CRP values (with standard errors of mean) in patients with an acute exacerbation of COPD were significantly higher (PZ 0.0006)
compared with healthy controls and stable COPD patients (PZ 0.003). (b) Comparison of serum PCT (with standard errors of mean)
in healthy controls, in patients with COPD, and in patients with an acute exacerbation of COPD. Differences did not reach the level
of significance. (c) Comparison of WBC (with standard errors of mean) in healthy controls, in patients with COPD, and in patients
with an acute exacerbation of COPD. WBC levels in patients with an acute exacerbation of COPD were higher compared with
healthy controls (PZ 0.0006) and stable COPD patients (PZ 0.0007). (d) Correlation between CRP and AAT in serum of patients
with an acute exacerbation of COPD. Spearman’s correlation reached 0.87 (PZ 0.000003).
124 A.R. Koczulla et al.COPD patients had significantly elevated AAT levels
compared with healthy controls.
One might speculate that stable COPD patients might
have higher AAT EBC levels compared with healthy controls
because of neutrophil burden. Another idea might be an
interaction of AAT with neutrophils like described before.26
Further experiments are necessary to prove these
speculations.
WBC count, PCT, and CRP all showed elevated values in
the exacerbated COPD group however, only WBC and CRP
values reached significance compared with healthy controls
and stable COPD patients.
By standard clinical measures patients with pneumonia
were excluded. The large range observed for CRP and WBC
was considered as a reflection of random scatter in a small
sample.An increase in inflammation markers like CRP has also
been shown in other studies for acute exacerbated COPD
patients.17e19 Although CRP was the most useful biomarker
of the 36 plasma biomarkers assessed in the study reported
by Hurst et al,17 plasma biomarkers were not found to be
useful in predicting the clinical severity of exacerbation.
One important point is that only serum parameters were
analyzed in the latter study. Since COPD exacerbations are
difficult to diagnose, AAT might have the potential to serve
as an additional marker of COPD exacerbations in the
future, especially when considering both local and systemic
approaches, as COPD exacerbations are likely to have
a systemic component. Since AAT is an acute-phase protein
and a regulator of inflammation, it may also be elevated in
other inflammatory conditions and be present as a non-
specific inflammatory marker. As yet, local and systemic
AAT levels in COPD Exacerbations 125levels of AAT have not been investigated in patients with
non-COPD inflammatory disease.
This study showed that AAT is elevated in serum of
exacerbated COPD patients. There are limited data on the
serum elevation of AAT in COPD patients.21 CRP and PCT are
commonly used serumparameters tomeasure inflammation.
PCT is elevated in sepsis and bacterial infection.22,23 CRP is
elevated in bacterial and autoimmune inflammation and
non-specifically reflects systemic inflammation. Recent data
suggest that CRP is elevated during an acute exacerbation of
COPD, but CRP alone is neither sensitive nor specific in pre-
dicting clinical severity or outcome. Copeptin increases
during acute exacerbation of COPD and may correlate with
disease severity.24 In our study, serum PCT and CRP corre-
lated with elevated serum AAT, in exacerbated COPD
subjects but the local increase of AAT in the EBC of patients
with acute exacerbations of COPD was not associated with
PCT, CRP, and WBC count. A correlation for EBC AAT with
WBC was found calculating for all included subjects.
This study showed that, when using a suitable assay, AAT
could be measured in the EBC of all subjects, including
healthy controls, patients with COPD, and patients with
acute exacerbations of COPD. The consistency of the data
also indicated that the method was reproducible. The study
has some limitations; only a small number of patients were
included and the design of the study was cross-sectional
with only one time point. Although only a small number of
patients were included in the experiments, we were able to
demonstrate in that explorative study that AAT was
elevated in COPD exacerbations. The small number of
patients included was of course more prone to be influ-
enced by outliers in the data, which also cause larger
standard deviations. We therefore consider the correlations
observed only as confirmations of the consistency of the
data and would not consider these as clinically relevant at
the current state of knowledge.
As we only studied one time point directly after the
patients were admitted to the emergency room, it would be
interesting to determine if and when the level of AAT
decreases, and if this decrease is correlated with clinical
improvements.
The group of healthy controls included in the study was
younger than the patients with COPD and not matched for
age, which might have resulted in a bias. However, it could
be shown from the levels of nitrate and nitrite in EBC that
age was not a major confounder.25 Furthermore, we could
also detect a significant difference in AAT levels (both local
AAT levels and systemic AAT levels being increased) in
exacerbated COPD patients comparedwith the age-matched
group of stable COPD patients which and were the major
focus of that proof of concept study.
Regarding the content of proteins in the EBC, the ATS/ERS
task force has highlighted that one current limitation of EBC
measurement is the low concentration of many biomarkers,
and therefore their measurement may be limited by the
sensitivity of theassays.7 Thedevelopment ofhighly sensitive,
reproducible ELISA assays aims to improve this limitation.
Another point of criticism regarding the use of EBC is the
lack of standardization of the condensate measurements.
Both a time-dependent measurement and a volume-
controlled measurement are possible. It is not yet known
whether airflow obstruction has a major effect on the levelsof protein in EBC and a validation factor for EBC measure-
ments is not yet available.
Conclusion
In conclusion, we found in that explorative study that
collection of EBC is simple to perform in stable COPD and in
patients with acute exacerbations of COPD. AAT could
prove to be an important marker protein in the exacerba-
tion of COPD. The source of the measured AAT must be
more clearly defined in future experiments as it has not
been defined whether it is of local origin or is part of the
systemic increase. The sensitivity and specificity for AAT as
a biomarker for detecting acute exacerbated COPD appears
to be worthy of further examination.
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